Kinetic analysis of daily hemofiltration

Background: Daily hemofiltration (D‐HF) is a new treatment modality that shows unique solute removal characteristics and possibly provides a high quality of life for patients with end‐stage renal disease. We evaluated solute removal characteristics of D‐HF for five patients by kinetic modeling analysis. Methods: Five patients treated with normal 3 × 4 hr/week hemodialysis (HD) were switched to D‐HF (6 × 2 hr/week). Ultrafiltration rates (Q_F) or small‐solute clearances ranged from 63 to 106 mL/min. All the necessary kinetic parameters were determined from patients' physical data and HD portion of the clinical measurements. The two‐compartment kinetic model predicted the concentration changes after switching from normal HD to D‐HF. Results: Concentrations of small solutes such as urea nitrogen (UN) increased, whereas that of β₂‐microglobulin (β₂‐MG) decreased after switching from normal HD to D‐HF in all five patients. Predicted solute concentrations and clinical measurements for UN and β₂‐MG were in good agreement with mean error less than 10%. The model predicted that Q_F = 155 mL/min may be necessary for time‐averaged concentration (TAC) of UN to be unchanged. The model also predicted that the 7 times/week D‐HF should not increase the pretreatment concentration of UN, expecting even much lower β₂‐MG concentration after switching from normal HD to D‐HF. Conclusion: D‐HF is superior to normal HD for removing larger solutes but may increase the TAC of small solutes. Seven‐day (7 times/week) D‐HF may improve the solute removal capacity of small solutes.     

Kinetic Studies on Urea Extraction with Hemodialysis in Adolescents by On‐line Monitoring of Dialysate Urea

Kinetics of urea extraction during a single dialysis session in children are unknown, because analysis of solutes in dialysate is difficult due to their extreme dilution. >Objective: A novel urea monitor of the Gambro Company might be of help in studying urea kinetics also in children. Methods: We studied 107 urea kinetics in 5 adolescents aged 13–19 years, weighing 26–58 kg, and looked for influences of membrane size, blood flow, and duration of one dialysis session. Urea measurement applies to the change of electric dialysate conductivity due to ionization because of urea splitting by urease. Bicarbonate dialysis regimen was 4–5 h each, 3 times a week, using polysulfone high‐flux dialyzers (Fresenius F60 or F80, depending on body size). Results: Average 4‐h urea Kt/V values for F60 (n = 85) were 1.69±0.53 and for F80 (n = 21) 1.63±0.25, extracted urea mass was 16.0±5.4 g and 32.5±5.4 g, respectively (p < 0.05); Kt/V urea results for blood flows of 180–220 mL/min were 1.36±0.52 and for <180 mL/min 1.10±0.43; extracted urea mass was 17.3±8.0 and 11.7±4.9 g, respectively (p < 0.05). Total average urea extraction ratio after 2 h of dialysis (n = 107) was 64.8±5.6%. Extraction ratio during the 4^th h of dialysis was only 15.3±4.1% and during the 5^th h not more than 9.0±3.6% of total urea extraction. Conclusion: Kinetics of urea extraction helps understanding dialysis processes in children. Adapting the size of the dialyzer according to body size raises urea extraction and maintains urea clearance Kt/V at the desired quality level. An inadequate blood flow lowers both urea extraction and urea clearance Kt/V. Prolonging dialysis beyond 4 h is, at least in concern of urea kinetic modelling, a rather ineffective means. We speculate that children with blood flow problems should be dialysed more often.     

Long-Term Transport Study of Bioartificial Tubule Devices in the Development of a Bioartificial Kidney

Introduction: A bioartificial kidney, which consists of a continuous hemofilter and a bioartificial tubule device using proximal tubular epithelial cells (LLC‐PK₁), is desired to develop for preventing long‐term complications in hemodialysis patients. A bioartificial tubule device should function for a long duration in terms of the simplicity and the economy. Continuous hemofiltration with 10 L/day of filtrate could maintain plasma urea, creatinine and β₂‐microglobulin in patients at low levels compared to those in standard hemodialysis patients. Methods: 6 bioartificial tubule devices, in which LLC‐PK₁ cells were grown on the inner surfaces of hollow fiber capillaries (membrane area: 0.4 m², 1600 fibers), were used to evaluate the transport ability of H₂O, glucose and Na⁺, and leak rates of urea and creatinine for 2 weeks when the medium containing 50 mg/dL of urea and 5.0 mg/dL of creatinine was perfused inside of the cell‐attached membranes and another medium containing 2.5 g/dL of albumin was perfused outside of the membranes. Scanning electron micrograph of cross‐sectional findings of the hollow fibers was taken at 6, 10, and 14 days after formation of confluence. Results: By conversion into 1 m² of membrane area, transport of H₂O, glucose, and Na⁺ was 6266 ± 995 mL/day, 22832 ± 7240 mg/day, and 941.3 ± 180 mEq/day, respectively at 6 days after confluence. Leak rates of urea and creatinine across the cell‐attached membranes were 22 ± 6.1% and 19.2 ± 4.9 with albumin addition, whereas 13.1 ± 1.9% and 12.2 ± 1.6 without albumin addition. Transport capacity of these components and the leak rates had continued for 10–13 days, and decreased thereafter because of the formation of the multilayers. Bioartificial tubule devices with membrane area 1.0 m² can reach the targeted amounts of H₂O, glucose, and Na⁺ transports when 6 L of 10 L/day of hemofiltrate has to be regenerated, substituting 4 L with meal and drinks.     

Pharmacokinetic properties of indinavir in rat: some limitations of noncompartmental analysis

Background: Compartmental as well as noncompartmental analyses are used routinely in pharmacokinetic analysis. Materials and methods: Pharmacokinetic parameters of the anti-HIV agent, indinavir, have been determined in six male rats applying both the compartmental and the noncompartmental analysis. Results and discussion: A very slow declining phase was found in the indinavir plasma concentration profile using an extended sampling time period and applying a sensitive high-performance liquid chromatography assay method. This apparent terminal elimination phase can cause some significant errors when applying noncompartmental kinetic analysis to the data, with mean residence time (MRT) (544.2 ± 123.2 minutes), total systemic clearance (12.0 ± 2.1 mL/min/kg), and steady-state volume of distribution (V_d (ss)) (6.4 ± 1.0 L/kg) being highly different from the results of compartmental kinetic analysis (MRT, Cl_total, and V_d (ss) values of 23.7 ± 5.9 minutes, 35.18 ± 5.1 mL/min/kg, and 0.84 ± 0.28 L/kg, respectively). The parameters estimated by our noncompartmental approach were also significantly different from the results of the same type of data analysis reported in the literature. Conclusion: The differences in parameter estimations, while being a result of the extended plasma sampling period, which is recommended in noncompartmental analysis, support the priority of applying the compartmental analysis approach in the similar cases with some pre-assumptions, mainly ignoring the final apparent terminal elimination phase(s), very deep tissue, which involves very low drug concentrations.     

The Clinical Impact of Increasing the Hemodialysis Dose

Good evidence suggests that improvements in dialysis efficiency reduce morbidity and mortality of hemodialysis (HD) patients. Dialysis efficiency has also been related to better control of arterial blood pressure (BP), anemia, and serum phosphorus levels, and to improvement in patients' nutritional status. Over a 2‐year period, the present self‐controlled study of 34 HD patients (23 men, 11 women; age, 52.6 ± 14.5 years; HD duration, 55.9 ± 61.2 months) looked at the effect on clinical and laboratory parameters of increasing the delivered dialysis dose under a strict dry‐weight policy. Dialysis dose was increased without increasing dialysis time and frequency. A statistically significant increase was seen in delivered HD dose: the urea reduction ratio (URR) increased to 60% ± 10% from 52% ± 8%, and then to 71% ± 7% (p < 0.001); Kt/V_urea increased to 1.22 ± 0.28 from 0.93 ± 0.19, and then to 1.55 ± 0.29 (p < 0.001). A statistically significant increase in hemoglobin concentration also occurred—to 10.8 ± 1.9 g/dL from 10.4 ± 1.7 g/dL, and then to 11.0 ± 1.3 g/dL (p < 0.05 as compared to baseline)—with no significant difference in weekly erythropoietin dose. Statistically significant decreases occurred in the systolic and diastolic blood pressures during the first year; they then remained unchanged. Systolic blood pressure decreased to 131 ± 23 mmHg from 147 ± 24 mmHg (p < 0.001); diastolic blood pressure decreased to 65 ± 11 mmHg from 73 ± 12 mmHg (p < 0.001). Serum albumin increased insignificantly to 4.4 ± 0.4 g/dL from 4.3 ± 0.4 g/dL, and then significantly to 4.6 ± 0.3 g/dL (p = 0.002 as compared to both previous values). Normalized protein catabolic rate increased significantly to 1.16 ± 0.15 g/kg/day from 0.93 ± 0.16 g/kg/ day (p < 0.001), and then to 1.20 ± 0.17 g/kg/day (p < 0.001 as compared to baseline). We conclude that the increases achieved in average Kt/V_urea per hemodialysis session by increasing dialyzer membrane area, and blood and dialysate flows, without increasing dialysis time above 4 hours, in patients hemodialyzed thrice weekly, coupled with strict dry‐weight policy, resulted in improvements in hypertension, nutritional status, and anemia.     

Mixed Lead Halide Passivation of Quantum Dots

Infrared‐absorbing colloidal quantum dots (IR CQDs) are materials of interest in tandem solar cells to augment perovskite and cSi photovoltaics (PV). Today's best IR CQD solar cells rely on the use of passivation strategies based on lead iodide; however, these fail to passivate the entire surface of IR CQDs. Lead chloride passivated CQDs show improved passivation, but worse charge transport. Lead bromide passivated CQDs have higher charge mobilities, but worse passivation. Here a mixed lead‐halide (MPbX) ligand exchange is introduced that enables thorough surface passivation without compromising transport. MPbX–PbS CQDs exhibit properties that exceed the best features of single lead‐halide PbS CQDs: they show improved passivation (43 ± 5 meV vs 44 ± 4 meV in Stokes shift) together with higher charge transport (4 × 10^‐2 ± 3 × 10^‐3 cm² V^‐1 s^‐1 vs 3 × 10^‐2 ± 3 × 10^‐3 cm² V^‐1 s^‐1 in mobility). This translates into PV devices having a record IR open‐circuit voltage (IR V_oc) of 0.46 ± 0.01 V while simultaneously having an external quantum efficiency of 81 ± 1%. They provide a 1.7× improvement in the power conversion efficiency of IR photons (>1.1 µm) relative to the single lead‐halide controls reported herein.     

Urea standard Kt/Vurea for assessing dialysis treatment adequacy

Urea standard Kt/V_urea (stdKt/V_urea) has been proposed as a dose measure to assess the adequacy of dialysis treatments of arbitrary length and frequency. It is based on two fundamental assumptions: 1) that clinical outcomes for hemodialysis and peritoneal dialysis patients are equivalent and 2) that the equivalency of such clinical outcomes is achieved when the mean predialysis blood urea nitrogen or urea concentration is identical for both therapies. The relationships among urea stdKt/V_urea, equilibrated Kt/V_urea, and single‐pool Kt/V_urea are reviewed, and the assumptions required for the validity of urea stdKt/V_urea as a universal dose measure to describe dialysis treatment adequacy are discussed. It is proposed that urea stdKt/V_urea is a dose measure for both water‐soluble and protein‐bound toxin clearances; therefore, this parameter may be a practical dose measure for assessing the adequacy of dialysis during treatments of arbitrary length and frequency.     

An Overview of Uremic Toxicity

About 100 uremic retention solutes have been identified at present, but not all of these compounds are necessarily toxic. They can be defined as uremic toxins if they exert biochemical/biological actions. Based on their physicochemical characteristics, there are three major groups of uremic retention solutes: 1) the small water‐soluble compounds (<500 Da), which are easily removed by standard low‐pore‐size dialyzer membranes; 2) the protein‐bound solutes (also mostly <500 Da), whose dialytic removal is hampered by their protein binding, irrespective of the membrane type; and 3) the so‐called middle molecules (>500 Da), which can be removed only by membranes with a large pore size and/or adsorptive capacity. In the present review, we will summarize the currently known information about the toxicity of the uremic retention solutes. Although removal of small water‐soluble urea has been recognized for many years as a current measure of dialysis adequacy, data on its toxicity are very scanty. Almost 50 other water‐soluble compounds are known to be retained in uremia, but only a few exert biological effects. Most of the toxic water‐soluble moieties, such as the guanidines, phosphate, xanthine, and hypoxanthine show an intra‐dialytic compartmental behavior, which is different from urea. A substantial number of uremic solutes are protein bound, and most of them exert biological action. Among them are the phenols, indoles, homocysteine, and carboxy‐methyl‐propyl‐furanpropionic acid. Recent data suggest that protein binding acts as a buffer against the toxic effects of these compounds, and that hypoalbuminemia increases both their free fraction and their toxicity. In addition, many middle molecules, such as ß₂‐microglobulin, leptin, and advanced glycation end products, have been related to biological/clinical effects. Our current knowledge of the biological impact of the middle molecules is very likely incomplete. It is concluded that many of the water‐soluble compounds exert little or no toxicity, and that urea removal pattern per se is not identical to that of many biologically active molecules. Hence, in dialysis, more than urea removal alone should be pursued.     

Evaluation of partial pressure CO2 change in the dialyzer blood inlet during hemodialysis as a measure of vascular access recirculation

Introduction

Vascular access recirculation during hemodialysis is associated with reduced effectiveness and worse survival outcomes. To evaluate recirculation, an increase in pCO₂ in the blood of the arterial line during hemodialysis (threshold of 4.5 mmHg) was proposed. The blood returning from the dialyzer in the venous line has significantly higher pCO₂, so in the presence of recirculation, pCO2 in the arterial blood line may increase (ΔpCO₂) during hemodialysis sessions. The aim of our study was to evaluate ΔpCO₂ as a diagnostic tool for vascular access recirculation in chronic hemodialysis patients.

Methods

We evaluated vascular access recirculation with ΔpCO₂ and compared it with the results of a urea recirculation test, which is the gold standard. ΔpCO₂ was obtained from the difference in pCO₂ in the arterial line at baseline (pCO₂T1) and after 5 min of hemodialysis (pCO₂T2). ∆pCO₂ = pCO₂T2–pCO₂T1.

Findings

In 70 hemodialysis patients (mean age: 70.52 ± 13.97 years; hemodialysis vintage of 41.36 ± 34.54, KT/V 1.4 ± 0.3), ∆pCO₂ was 4 ± 4 mmHg, and urea recirculation was 7% ± 9%. Vascular access recirculation was identified using both methods in 17 of 70 patients, who showed a ∆pCO₂ of 10 ± 5 mmHg and urea recirculation of 20% ± 9%; time in months of hemodialysis was the only difference between vascular access recirculation and non-vascular access recirculation patients (22 ± 19 vs. 46 ± 36, p: 0.05). In the non-vascular access recirculation group, the average ΔpCO₂ was 1.9 ± 2 (p: 0.001), and the urea recirculation % was 2.8 ± 3 (p: 0.001). The ΔpCO₂ correlated with the urea recirculation % (R: 0.728; p < 0.001).

Discussion

ΔpCO₂ in the arterial blood line during hemodialysis is an effective and reliable diagnostic tool for identifying recirculation of the vascular access but not its magnitude. The ΔpCO₂ test application is simple and economical and does not require special equipment.     

Reduced protein bound uraemic toxins in vegetarian kidney failure patients treated by haemodiafiltration

Introduction Indoxyl sulfate (IS) and p cresyl sulfate (PCS) are protein bound toxins which accumulate with chronic kidney disease. Haemodiafiltration (HDF) increases middle molecule clearances and has been suggested to increase IS and PCS clearance. We therefore wished to establish whether higher convective clearances with HDF would reduce IS and PCS concentrations. Methods We measured total plasma IS and PCS in a cohort of 138 CKD5d patients treated by On‐line HDF (Ol‐HDF), by high pressure liquid chromatography. Findings Mean patient age was 64.6 ± 16.5 years, 60.1% male, 57.3% diabetic, median dialysis vintage 25.9 months (12.4–62.0). The mean ICS concentration was 79.8 ± 56.4 umol/L and PCS 140.3 ± 101.8 umol/L. On multivariate analysis, IS was associated with serum albumin (β 4.31,P < 0.001), and negatively with residual renal function (β‐4.1,P = 0.02) and vegetarian diet(β‐28.3, P = 0.048) and PCS negatively with log C reactive protein (β‐75.8, P < 0.001) and vegetarian diet (β‐109, P = 0.001). Vegetarian patients had lower IS and PCS levels (median 41.5 (24.2–71.9) vs. 78.1 (49.5–107.5) and PCS (41.6 (14.2–178.3) vs. 127.3 (77.4–205.6) µmol/L, respectively, P < 0.05. Vegetarian patients had lower preOl‐HDF serum urea, and phosphate (13.8 ±3.8 vs. 18.4 ± 5.2 mmol/L, and 1.33 ± 0.21 vs. 1.58 ± 0.45 mmol/L), and estimated urea nitrogen intake (1.25 ± 0.28 vs. 1.62 ± 0.5 g/kg/day), respectively, all P < 0.05. Discussion Plasma IS and PCS concentrations were not lower with Ol‐HDF compared to previous studies in haemodialysis patients. However those eating a vegetarian diet had reduced IS and PCS concentrations. Although this could be due to differences in dietary protein intake, a vegetarian diet may also potentially reduce IS and PCS production by the intestinal microbiome.     

Highly Luminescent 2D‐Type Slab Crystals Based on a Molecular Charge‐Transfer Complex as Promising Organic Light‐Emitting Transistor Materials

A new 2:1 donor (D):acceptor (A) mixed‐stacked charge‐transfer (CT) cocrystal comprising isometrically structured dicyanodistyrylbenzene‐based D and A molecules is designed and synthesized. Uniform 2D‐type morphology is manifested by the exquisite interplay of intermolecular interactions. In addition to its appealing structural features, unique optoelectronic properties are unveiled. Exceptionally high photoluminescence quantum yield (Φ _F ≈ 60%) is realized by non‐negligible oscillator strength of the S₁ transition, and rigidified 2D‐type structure. Moreover, this luminescent 2D‐type CT crystal exhibits balanced ambipolar transport (µ _h and µ _e of ≈10^?4 cm² V^?1 s^?1). As a consequence of such unique optoelectronic characteristics, the first CT electroluminescence is demonstrated in a single active‐layered organic light‐emitting transistor (OLET) device. The external quantum efficiency of this OLET is as high as 1.5% to suggest a promising potential of luminescent mixed‐stacked CT cocrystals in OLET applications.     

Stimulated sweating as a therapy to reduce interdialytic weight gain and improve potassium balance in chronic hemodialysis patients: A pilot study

Controlling the extracellular volume in hemodialysis patients is a difficult task. The aim of this study was to evaluate the capacity of different methods of stimulated sweating to reduce mean interdialytic weight gain (IWG), to improve blood pressure regulation, and potassium/urea balance. Two center, crossover pilot study. In Lausanne, hemodialysis patients took four hot‐water baths a week, 30 minutes each, on nondialysis days during 1 month. In Sfax, patients visited the local Hammam Center four times a week. Hemodynamic parameters were recorded, and weekly laboratory analysis was performed. Results were compared with a preceding 1‐month control period. In Lausanne, five patients (all men, median age 55 years) participated. Bathing temperature was (mean ± standard deviation) 41.2 ± 3°C and sweating‐induced weight loss 600 ± 500 g. Mean IWG (control vs. intervention period) decreased from 2.3 ± 0.9 to 1.8 ± 1 kg (P = 0.004), Systolic blood pressure from 139 ± 21 to 136 ± 22 mmHg (P = 0.4), and diastolic blood pressure form 79 ± 12 to 75 ± 13 mmHg (P = 0.08); antihypertensive therapy could be reduced from 2.8 ± 0.4 to 1.9 ± 0.5 antihypertensive drugs per patient (P = 0.01). In Sfax (n = 9, median age 46 years), weight loss per Hammam session was 420 ± 100 g. No differences were found in IWG or BP, but predialysis serum potassium level decreased from 5.9 ± 0.8 to 5.5 ± 0.9 mmol/L (P = 0.04) and urea from 26.9 ± 6 to 23.1 ± 6 mmol/L (P = 0.02). Hot‐water baths appear to be a safe way to reduce IWG in selected hemodialysis patients. Hammam visits reduce serum potassium and urea levels, but not IWG. More data in larger patient groups are necessary before definite conclusion can be drawn.     

Removal of vancomycin administered during dialysis by a high‐flux dialyzer

Introduction: Hemodialysis patients frequently receive vancomycin for treatment of gram‐positive bacterial infections. This drug is most conveniently administered in outpatient dialysis units during the hemodialysis treatment. However, there is a paucity of data on the removal of vancomycin by high‐flux polyamide dialyzers. Methods: This is a prospective crossover study in which seven uninfected chronic hemodialysis patients at three dialysis units received vancomycin 1 gram intravenously over one hour immediately after the dialysis treatment (Phase 1), and vancomycin 1.5 grams during the last hour of dialysis treatment using a polyarylethersulfone, polyvinylpyrrolidone, polyamide high‐flux (Polyflux 24R) dialyzer (Phase 2). There was a three‐week washout period between phases. Serial serum vancomycin concentrations were used to determine the removal of vancomycin when administered during dialysis. Findings: Dialysis removed 35 ± 15% (range 18‐56%) of the vancomycin dose when administered during the last hour of dialysis. The calculated area under the curve (AUC) of vancomycin levels for 0‐44.5 hours from the start of infusion were similar between the two phases (AUC_{Phase 1} 884 ± 124 mg‐hr/L, mean ± SD; AUC_{Phase 2} 856 ± 208 mg‐hr/L; P=0.72). Serum vancomycin concentrations immediately prior to the next dialysis treatment following vancomycin administration were also similar between the two phases (13.1 ± 2.7 mg/L in Phase 1 and 12.3 ± 3.3 mg/L in Phase 2; P=0.55). Discussion: When using a polyarylethersulfone, polyvinylpyrrolidone, and polyamide high‐flux HD membrane with a 24R Polyflux dialyzer, vancomycin can be administered during the last hour of dialysis if the dose that is prescribed for intra‐dialysis dosing is empirically increased to account for intra‐dialytic drug removal.     

Optimization of the Pore Structures of MOFs for Record High Hydrogen Volumetric Working Capacity

Metal–organic frameworks (MOFs) are promising materials for onboard hydrogen storage thanks to the tunable pore size, pore volume, and pore geometry. In consideration of pore structures, the correlation between the pore volume and hydrogen storage capacity is examined and two empirical equations are rationalized to predict the hydrogen storage capacity of MOFs with different pore geometries. The total hydrogen adsorption under 100 bar and 77 K is predicted as n_tot= 0.085× V_p − 0.013× V_p² for cage-type MOFs and n_tot= 0.076× V_p − 0.011× V_p² for channel-type MOFs, where V_p is the pore volume of corresponding MOFs. The predictions by these empirical equations are validated by several MOFs with an average deviation of 5.4%. Compared with a previous equation for activated carbon materials, the empirical equations demonstrate superior accuracy especially for MOFs with high surface area (i.e., S_BET over ≈3000 m² g⁻¹). Guided by these empirical equations, a highly porous Zr-MOF NPF-200 (NPF: Nebraska Porous Framework) is examined to possess outstanding hydrogen total adsorption capacity (65.7 mmol g⁻¹) at 77 K and record high volumetric working capacity of 37.2 g L⁻¹ between 100 and 5 bar at 77 K.     

Isotherm,kinetic, and thermodynamic studies on the adsorption behavior of malachite green dye onto montmorillonite clay

ABSTRACT

Systematic batch mode studies of adsorption of malachite green (MG) on montmorillonite clay were carried out as a function of process parameters which include pH, adsorbent dosage, agitation speed, ionic strength, initial MG concentration, and temperature. Montmorillonite was found to have excellent adsorption capacity. Equilibrium adsorption isotherms were measured for the single-component system, and the experimental data were analyzed by using Langmuir, Freundlich, Temkin, and Dubinin–Radushkevich isotherm equations. It was found that the Langmuir equation appears to fit the equilibrium data. The monolayer (maximum) adsorption capacity (q_m) was found to be 262.494 mg g^?1 for montmorillonite. The experimental kinetic data were analyzed using the first-order, second-order, Elovich, and intraparticle kinetic models and the second-order kinetic model described the adsorption kinetics accurately for MG. Thermodynamic activation parameters such as ΔG*, ΔS*, and ΔH* of the adsorption of MG on montmorillonite were also calculated.     

Manipulation of Charge Transport by Metallic V13O16 Decorated on Bismuth Vanadate Photoelectrochemical Catalyst

Conductive metal oxides represent a new category of functional material with vital importance for many modern applications. The present work introduces a new conductive metal oxide V₁₃O₁₆, which is synthesized via a simplified photoelectrochemical procedure and decorated onto the semiconducting photocatalyst BiVO₄ in controlled mass percentages ranging from 25% to 37%. Owing to its excellent conductivity and good compatibility with oxide materials, the metallic V₁₃O₁₆‐decorated BiVO₄ hybrid catalyst shows a high photocurrent density of 2.2 ± 0.2 mA cm^?2 at 1.23 V versus reversible hydrogen electrode (RHE). Both experimental characterization and density functional theory calculations indicate that the superior photocurrent derives from enhanced charge separation and transfer, resulting from ohmic contact at the interface of mixed phases and superior electrical conductivity from V₁₃O₁₆. A Co–Pi coating on BiVO₄–V₁₃O₁₆ further increases the photocurrent to 5.0 ± 0.5 mA cm^?2 at 1.23 V versus RHE, which is among the highest reported for BiVO₄‐based photoelectrodes. Surface photovoltage and transient photocurrent measurements suggest a charge‐transfer model in which photocurrents are enhanced by improved surface passivation, although the barrier at the Co–Pi/electrolyte interface limits the charge transfer.     

Modifications to bicarbonate conductivity: A way to increase phosphate removal during hemodialysis? Proof of concept

Introduction Hyperphosphatemia and cardiovascular mortality are associated particularly with end‐stage renal disease. Available therapeutic strategies (i.e., diet restriction, calcium [or not]‐based phosphate binders, calcimimetics) are associated with extrarenal blood purification. Compartmentalization of phosphate limits its depuration during hemodialysis. Several studies suggest that plasmatic pH is involved in the mobilization of phosphate from intracellular to extracellular compartments. Consequently, the efficiency of modified bicarbonate conductivity to purify blood phosphate was tested. Methods Ten hemodialysis patients with chronic hyperphosphatemia (>2.1 mmol/L) were included in the two three–sessions‐per week periods. Bicarbonate concentration was fixed at 40 mmol/L and 30 mmol/L in the first and second periods, respectively. Phosphate depuration was evaluated by phosphate mobilization clearance (K_M). Findings Although bicarbonatemia was lower during the second period (21.0 ± 2.7 vs. 24.4 ± 3.1 mmol/L, P < 0.01), no difference was observed in phosphatemia (2.4 ± 0.5 vs. 2.3 ± 0.4 mmol/L, P = NS). The in‐session variation of phosphate was lower (?1.45 ± 0.42 vs. ?1.58 ± 0.44 mmol/L, P < 0.05) and K_M was higher during the second period (82.94 ± 38.00 vs. 69.74 ± 24.48 mL/min, P < 0.05). Discussion The decrease of in‐session phosphate and the increase in K_M reflect phosphate refilling during hemodialysis. Thus, modulation of serum bicarbonate may play a role in controlling the phosphate pool. Even though correcting metabolic acidosis during hemodialysis remains important, alkaline excess can impair phosphate mobilization clearance. Clinical trials are needed to test the efficiency and relevance of a strategy where bicarbonatemia is corrected less at the beginning of sessions.     

A 1300 mm2 Ultrahigh‐Performance Digital Imaging Assembly using High‐Quality Perovskite Single Crystals

By fine‐tuning the crystal nucleation and growth process, a low‐temperature‐gradient crystallization method is developed to fabricate high‐quality perovskite CH₃NH₃PbBr₃ single crystals with high carrier mobility of 81 ± 5 cm² V^?1 s^?1 (>3 times larger than their thin film counterpart), long carrier lifetime of 899 ± 127 ns (>5 times larger than their thin film counterpart), and ultralow trap state density of 6.2 ± 2.7 × 10⁹ cm^?3 (even four orders of magnitude lower than that of single‐crystalline silicon wafers). In fact, they are better than perovskite single crystals reported in prior work: their application in photosensors gives superior detectivity as high as 6 × 10¹³ Jones, ≈10–100 times better than commercial sensors made of silicon and InGaAs. Meanwhile, the response speed is as fast as 40 µs, ≈3 orders of magnitude faster than their thin film devices. A large‐area (≈1300 mm²) imaging assembly composed of a 729‐pixel sensor array is further designed and constructed, showing excellent imaging capability thanks to its superior quality and uniformity. This opens a new possibility to use the high‐quality perovskite single‐crystal‐based devices for more advanced imaging sensors.